The short version: public ads for peptide medicines are banned
In Australia, advertising prescription medicines to the public is prohibited. Most “peptides” promoted for healing, muscle growth, anti‑ageing, skin, hair, sexual health or weight loss are either:
- Schedule 4 (Prescription Only) medicines under the Poisons Standard (e.g., semaglutide, tirzepatide), or
- Unapproved therapeutic goods (e.g., BPC‑157, TB‑500, many cosmetic/“research” peptides).
If a product is prescription‑only or an unapproved therapeutic good, you cannot advertise it to the public. Clinics can advertise a consultation, but not specific S4 medicines, brand names, or implied availability of a particular peptide.
Who sets the rules?
Multiple regulators and laws shape peptide advertising in Australia:
- TGA (Therapeutic Goods Administration): Therapeutic Goods Act 1989, Regulations, and the Therapeutic Goods Advertising Code regulate advertising of therapeutic goods to the public.
- AHPRA and National Boards: Advertising guidelines for regulated health services restrict how clinics and registered practitioners promote services (e.g., no testimonials in advertising, no misleading claims).
- ACCC: Australian Consumer Law applies across all advertising (truthful, not misleading, substantiated).
- State/Territory medicines and poisons laws: implement the Poisons Standard (SUSMP) that schedules prescription‑only substances.
Related reading: Are Peptides Legal in Australia?, Peptides Without Prescription Australia, Peptide Prescription Australia.
What clinics cannot claim or promote
If you provide medical, cosmetic, or telehealth services, these points are critical:
- No public advertising of prescription‑only medicines (S4) or unapproved peptides, including by brand or common name (e.g., “BPC‑157”, “TB‑500”, “CJC‑1295”, “PT‑141”, “semaglutide/Ozempic”, “tirzepatide/Mounjaro”).
- No direct or implied availability of a specific prescription product (e.g., “We prescribe BPC‑157” or “Get Ozempic now”). You may advertise a weight‑management consultation in general terms.
- No therapeutic claims unless they are consistent with TGA‑approved indications for an approved good. Unapproved peptides have no approved indications.
- No testimonials in advertising of regulated health services (AHPRA). This includes patient reviews, star ratings, and success stories used as advertising.
- Avoid before‑and‑after images where they imply therapeutic outcomes of a regulated health service or prescription medicine.
- No guarantees (“guaranteed results”, “no side effects”, “zero downtime”), and avoid overstating benefits or downplaying risks.
- No gifts, discounts, or inducements without clear and prominent terms and conditions (AHPRA requirement). Avoid inducements related to prescription‑only goods.
- No influencer, affiliate, or paid testimonial content promoting therapeutic use to the public. Social media “patient journeys” can be advertising if they encourage use.
- No off‑label or comparative claims targeted to the public (e.g., “BPC‑157 heals tendons faster than surgery”).
- No claims that a compounded prescription product is “the same as” a brand medicine, or otherwise equivalent or superior.
Related: Peptide Clinics Australia, Telehealth Peptide Clinic Australia, Peptide Clinic Reviews Australia, Peptide Before and After Guide, Peptide Reviews Guide.
What “sellers” and grey‑market sites cannot claim
Many websites try to bypass the rules with “research peptide”, “not for human use”, or “sold for lab use only.” These strategies do not make unlawful supply or advertising lawful when therapeutic claims are present.
- You cannot advertise to the public a product that is a prescription‑only medicine or an unapproved therapeutic good with implied therapeutic use.
- “Not for human consumption” disclaimers do not excuse therapeutic claims, dosing charts, human‑use instructions, or customer testimonials about results.
- You cannot import and supply peptides to others under the Personal Importation Scheme. That scheme is for an individual patient obtaining a medicine for themselves under strict conditions, not for retail or brokering.
- Claims like “legal in Australia”, “TGA approved”, or “pharmacy grade” must be accurate and substantiated. Most peptides promoted online are not TGA‑approved goods.
- Logos, look‑alike packaging, and brand references that imply TGA approval or pharmacy dispensing are high‑risk and likely misleading.
Related: Buy Peptides Australia, Can You Buy Peptides Online in Australia?, Can You Import Peptides Into Australia?, Peptide Personal Importation Scheme Australia, Counterfeit Peptides Australia.
Social media and SEO pitfalls that breach the Code
- Hashtags and captions that name prescription‑only or unapproved peptides with promised outcomes.
- Patient “story” posts or reels that function as testimonials or imply availability of a prescription medicine via your clinic.
- Linking ads to landing pages that name S4 medicines or present dose charts, protocols, or before‑and‑after photos.
- Influencer or affiliate content giving personal experience or endorsements about therapeutic use.
- Comparison blogs that target consumers with specific prescription product names and performance claims.
Safer approach: focus on general education about conditions and evidence quality without naming prescription products or unapproved peptides, and direct the public to seek individual clinical assessment.
Compounded peptides and advertising
Compounded medicines that are prescription‑only remain subject to the public advertising ban for prescription medicines. You cannot advertise a specific compounded peptide to the public, claim equivalence to a brand medicine, or present dosing/efficacy claims.
Clinics can describe services in general terms (e.g., “medical weight management consultations”) but should not imply a particular prescription medicine will be provided. Any discussion of medicines must occur in a clinical context with a practitioner.
Related: Compounded Peptides Australia, Prescription Only Peptides Australia, Can Doctors Prescribe Peptides in Australia?, Can GPs Prescribe Peptides in Australia?.
What you can usually say instead (safer wording)
The following examples avoid naming prescription‑only or unapproved products and keep the focus on the service:
- “Medical weight‑management consultations with qualified clinicians. Individual treatment decisions are made case‑by‑case.”
- “Skin and hair assessments with evidence‑based options discussed during your consult.”
- “Assessment‑led care for musculoskeletal concerns. Treatment plans are individualised after clinical review.”
- “Telehealth consultations available Australia‑wide. Medicines may be considered if clinically appropriate.”
Avoid listing specific peptide names, brand names, dosing protocols, or making efficacy promises in public‑facing materials.
Enforcement and penalties
The TGA actively monitors and responds to unlawful advertising of therapeutic goods. Enforcement tools include warning letters, takedown requests, infringement notices (fines), public naming of non‑compliance, and civil or criminal court action for serious or repeated contraventions. AHPRA may also take action for breaches of health service advertising rules, including use of testimonials.
If you receive a TGA compliance contact, act quickly, remove non‑compliant content, and seek advice. Proactive reviews of websites, landing pages, and social media reduce risk.
Special note on GLP‑1 and dual agonists (Ozempic, Wegovy, Mounjaro, tirzepatide)
These are prescription‑only medicines. You cannot advertise them to the public by name or implication. Clinics can discuss weight‑management services without naming specific medicines. Consumer‑directed pages that list brand names, show average weight‑loss results, or compare products are likely to breach the advertising ban.
Learn more: GLP‑1 Australia Guide, Semaglutide for Weight Loss, Tirzepatide for Weight Loss, Semaglutide vs Tirzepatide.
Frequently asked questions
Can I mention peptide names on my clinic website?
Not if they are prescription‑only or unapproved therapeutic goods. Public advertising of prescription medicines is prohibited, and unapproved goods cannot be advertised with therapeutic claims.
Are testimonials allowed if they are genuine?
No, not in advertising of regulated health services. AHPRA prohibits using testimonials in advertising, even if genuine.
Does “research peptide — not for human use” make it okay to advertise?
No. Disclaimers do not fix unlawful therapeutic claims, dosing instructions, or implied human use.
Can I run Google or social ads about peptides?
Public ads naming prescription‑only or unapproved peptides or implying their availability are not permitted. Focus on service‑level messaging without product names.
What about before‑and‑after photos?
If they imply outcomes from a regulated health service or a prescription medicine, they are high‑risk and often non‑compliant. AHPRA also restricts use where they could mislead.
Can a pharmacy or compounder advertise custom peptides?
Advertising prescription‑only compounded medicines to the public is not permitted. Professional communications to prescribers are different from public advertising.
What is a compliant alternative?
Advertise consultations and assessments in general terms, avoid naming specific medicines, present balanced information, and direct consumers to discuss options with a clinician.
Where can I read broader legality guidance?
See Are Peptides Legal in Australia?, Unapproved Peptides Australia, and Can You Import Peptides Into Australia?.
Is this legal advice?
No. This page provides general information only. Seek formal advice for your specific situation.
Ask a compliance question
Send your draft copy or URL for a quick, plain‑English check against Australian peptide advertising rules.
Key takeaway
In Australia, most peptide products people search for are prescription‑only or unapproved — and you cannot advertise them to the public. Focus public‑facing content on services and assessments, avoid product names and therapeutic promises, and ensure your materials comply with both the TGA Advertising Code and AHPRA rules.